178 related articles for article (PubMed ID: 34298356)
21. TBE booster immunization in adults--first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer.
Zent O; Schwarz TF; Plentz A; Banzhoff A; Jilg W
Int J Med Microbiol; 2004 Apr; 293 Suppl 37():134-8. PubMed ID: 15146995
[TBL] [Abstract][Full Text] [Related]
22. Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity.
Ehrlich HJ; Pavlova BG; Fritsch S; Poellabauer EM; Loew-Baselli A; Obermann-Slupetzky O; Maritsch F; Cil I; Dorner F; Barrett PN
Vaccine; 2003 Dec; 22(2):217-23. PubMed ID: 14615149
[TBL] [Abstract][Full Text] [Related]
23. A systematic literature review of the effectiveness of tick-borne encephalitis vaccines in Europe.
Angulo FJ; Zhang P; Halsby K; Kelly P; Pilz A; Madhava H; Moïsi JC; Jodar L
Vaccine; 2023 Nov; 41(47):6914-6921. PubMed ID: 37858450
[TBL] [Abstract][Full Text] [Related]
24. Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur Children.
Wittermann C; Petri E; Zent O
Vaccine; 2009 Mar; 27(10):1585-8. PubMed ID: 19162115
[TBL] [Abstract][Full Text] [Related]
25. Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization schedule.
Zent O; Jilg W; Plentz A; Schwarz TF; Frühwein N; Kuhr HB; Banzhoff A
Vaccine; 2003 Dec; 21(32):4655-60. PubMed ID: 14585672
[TBL] [Abstract][Full Text] [Related]
26. Persistence of protective immunity following vaccination against tick-borne encephalitis--longer than expected?
Rendi-Wagner P; Kundi M; Zent O; Dvorak G; Jaehnig P; Holzmann H; Mikolasek A; Kollaritsch H
Vaccine; 2004 Jul; 22(21-22):2743-9. PubMed ID: 15246606
[TBL] [Abstract][Full Text] [Related]
27. Response to tick-borne encephalitis (TBE) booster vaccination after prolonged time intervals to primary immunization with the rapid schedule.
Schöndorf I; Schönfeld C; Nicolay U; Zent O; Banzhoff A
Int J Med Microbiol; 2006 May; 296 Suppl 40():208-12. PubMed ID: 16531118
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of the tick-borne encephalitis vaccination (2009-2019): A systematic review.
Rampa JE; Askling HH; Lang P; Zens KD; Gültekin N; Stanga Z; Schlagenhauf P
Travel Med Infect Dis; 2020; 37():101876. PubMed ID: 32931931
[TBL] [Abstract][Full Text] [Related]
29. TBE booster immunization according to the rapid immunization schedule: are 3-year booster intervals really necessary?
Zent O; Plentz A; Schwarz TF; Frühwein N; Kuhr HB; Broeker M; Banzhoff A; Jilg W
Vaccine; 2004 Dec; 23(3):312-5. PubMed ID: 15530673
[TBL] [Abstract][Full Text] [Related]
30. Comparable immune responsiveness but increased reactogenicity after subcutaneous versus intramuscular administration of tick borne encephalitis (TBE) vaccine.
Hopf S; Garner-Spitzer E; Hofer M; Kundi M; Wiedermann U
Vaccine; 2016 Apr; 34(17):2027-34. PubMed ID: 26768126
[TBL] [Abstract][Full Text] [Related]
31. Analysis of delayed TBE-vaccine booster after primary vaccination.
Aerssens A; Cochez C; Niedrig M; Heyman P; Kühlmann-Rabens I; Soentjens P
J Travel Med; 2016 Feb; 23(2):tav020. PubMed ID: 26858269
[TBL] [Abstract][Full Text] [Related]
32. A cross-sectional study evaluating tick-borne encephalitis vaccine uptake and timeliness among adults in Switzerland.
Zens KD; Baroutsou V; Sinniger P; Lang P
PLoS One; 2021; 16(12):e0247216. PubMed ID: 34905534
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of tick-borne encephalitis vaccination in Latvia, 2018-2020: an observational study.
Zavadska D; Freimane Z; Karelis G; Ermina I; Harper LR; Bender C; Zhang P; Angulo FJ; Erber W; Bormane A; Gutmane E; Litauniece ZA; Tihonovs J; Griskevica A; Madhava H; Jodar L
Clin Microbiol Infect; 2023 Nov; 29(11):1443-1448. PubMed ID: 37422077
[TBL] [Abstract][Full Text] [Related]
34. [Tick-Borne Encephalitis - Viral Transmission and Considerations for Vaccination].
Zens KD
Ther Umsch; 2022 Nov; 79(9):471-481. PubMed ID: 36303529
[TBL] [Abstract][Full Text] [Related]
35. Tick-borne encephalitis (TBE) in Switzerland: does the prolongation of vaccine booster intervals result in an increased risk of breakthroughs?
Schmidt AJ; Altpeter E; Graf S; Steffen R
J Travel Med; 2022 Mar; 29(2):. PubMed ID: 34581402
[TBL] [Abstract][Full Text] [Related]
36. Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules.
Costantini M; Callegaro A; Beran J; Berlaimont V; Galgani I
Hum Vaccin Immunother; 2020 Sep; 16(9):2274-2279. PubMed ID: 31951780
[TBL] [Abstract][Full Text] [Related]
37. Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up.
Beran J; Lattanzi M; Costantini M; Pammolli A; Galgani I
Vaccine; 2023 May; 41(23):3518-3524. PubMed ID: 37142462
[TBL] [Abstract][Full Text] [Related]
38. Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety.
Beran J; Xie F; Zent O
Vaccine; 2014 Jul; 32(34):4275-80. PubMed ID: 24950352
[TBL] [Abstract][Full Text] [Related]
39. Comparison of immunogenicity and safety between two paediatric TBE vaccines.
Pöllabauer EM; Pavlova BG; Löw-Baselli A; Fritsch S; Prymula R; Angermayr R; Draxler W; Firth C; Bosman J; Valenta B; Harmacek P; Maritsch F; Barrett PN; Ehrlich HJ
Vaccine; 2010 Jun; 28(29):4680-5. PubMed ID: 20433803
[TBL] [Abstract][Full Text] [Related]
40. TBE infection in an incomplete immunized person at-risk who lives in a high-endemic area--impact on current recommendations for immunization of high-risk groups.
Plísek S; Honegr K; Beran J
Vaccine; 2008 Jan; 26(3):301-4. PubMed ID: 18082914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
